首页(2021改版)(2)中欧超声心动图继续教育巡讲2023年中意ALS大会中欧ALS病例魔方中欧渐冻症病例魔方第一章第二章第三章第四章第五章第六章第七章第八章第九章第十章中欧心动图继续教育第一节课程第三节课程第五节课程第六节课程第九节课程第十节课程第十一节课程第十三节课程第十四节课程瑞莫杜林患者教育视频第七节课程第五届肺动脉高压高峰论坛肺高血压继续教育第一节课程第二节课程第三节课程第四节课程第五节课程第六节课程第七节课程第八节课程第九节课程第十节课程第十一节课程第十二节课程心力衰竭继续教育第一课第二课第三课第四课第五课新冠疫情带来的心理影响李氏大药厂控股有限公司曲唑酮上市研讨会抑郁症伴失眠症状的治疗专场抑郁障碍伴失眠的管理专场突发公共事件中精神压力对脑健康的影响专场青少年抑郁的特征与转归专场《中国睡眠障碍综合防治指南》解读专场失眠、抑郁及躯体疾病的关系专场失眠及抑郁药物治疗策略专场老年人的失眠与抑郁专场睡眠—觉醒的机制专场抑郁障碍与睡眠障碍专场规范同治。安眠有“李”曲唑酮在睡眠障碍上的最新研究进展(一)曲唑酮在睡眠障碍上的最新研究进展(二)抑郁及睡眠医学教育项目Matrix项目——多科室病例魔方Video妇儿继续教育项目1妇儿继续教育项目尿素循环障碍教育视频第一届中欧心脏病学前沿论坛第二届中欧心脏病学前沿论坛中欧心脏病学前沿论坛中欧妇科学前沿论坛2022年脑心联盟俱乐部教育项目Breaking News阿齐沙坦布累迪宁在肾病的应用肾移植指南共识肾移植供体选择布累迪宁产科儿科妇科内分泌科肾内科消化内科外科围手术期心内科肿瘤科其他菲普利盖世龙ICUTPN丙戊酸毒性儿科肝病基础研究老年科男科内分泌科其他肾内及血透科心内科心衰合并肾衰心外科药学相关孕产科肿瘤科FDA左卡尼汀说明书相关参考文献NKF-KDOQI指南推荐可益能DICDVT和PTEICU儿科妇产科骨科呼吸内科泌尿外科普外科其他烧伤科神经外科神内科肾内科生殖消化科心内科肿瘤科立迈青利鲁唑机制临床研究循证医学证据指南共识综述迈通诺普卢利沙星失眠(含共病)抑郁焦虑曲唑酮锐思力白内障术后除眼表外眼科手术术后干眼角膜上皮损伤睑板腺功能障碍角膜塑形镜角膜移植其它眼表手术术后翼状胬肉术后准分子术后睿保特速乐涓尤靖安再宁平左卡尼汀口服溶液馥霖安芮旎爾瑞本钠平立畅青益生菌心胸外科新生儿科INOMAX的无创应用指南共识INOMAX速乐涓专家共识城市巡讲会

左卡尼汀用于心血管疾病的二级预防:系统综述和荟萃分析 L-Carnitine in the Secondary Prevention of Cardiovascular Disease Systema

Abstract

Objective: To evaluate the effects of L-carnitine compared with placebo or control on morbidity and mortality in the setting of acute myocardial infarction.

Methods: A systematic review and meta-analysis of 13 controlled trials (N=3629) was conducted to determine the effects of L-carnitine vs placebo or control on mortality, ventricular arrhythmias (VAs),angina, heart failure, and reinfarction. These trials were identified via searches of the Ovid MEDLINE,PubMed, and Excerpta Medica (Embase) databases between May 1, 2012, and August 31, 2012 Results: Compared with placebo or control, L-carnitine was associated with a significant 27% reduction in all-cause mortality (odds ratio, 0.73; 95% CI, 0.54-0.99; P=.05; risk ratio [RR],0.78; 95% CI, 0.60-1.00;

P=.05), a highly significant 65% reduction in VAs (RR, 0.35; 95% CI, 0.21-0.58; P<.0001), and a significant 40% reduction in the development of angina (RR, 0.60; 95% CI, 0.50-0.72; P<.00001), with no reduction in the development of heart failure (RR, 0.85; 95% CI, 0.67-1.09; P=.21) or myocardial reinfarction (RR,0.78; 95% CI, 0.41一1.48; P=.45)

Conclusion: Compared with placebo or control, L-carnitine is associated with a 27% reduction in all-causemortality, a 65% reduction in VAs, and a 40% reduction in anginal symptoms in patients experiencing an acute myocardial infarction. Further study with large randomized controlled trials of this inexpensive andsafe therapy in the modern era is warranted



详情请点击下载PDF文件。


一起探索

最有价值的医学知识

website qrcode

扫描查看手机版网站

会员登录
获取验证码
登录
登录
留言
回到顶部